HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases
Open Access
- 14 February 2021
- Vol. 10 (2), 152
- https://doi.org/10.3390/biology10020152
Abstract
Tyrosine kinase inhibitors (TKIs) are the treatment of choice for BCR-ABL1-positive chronic myeloid leukemia (CML). Although TKIs have substantially improved prognosis of CML patients, their use is not free of adverse effects. Dasatinib is a second generation TKI frequently associated with pleural effusion in up to 33% of patients. This results in symptoms as dyspnea, cough and chest pain that may require therapy discontinuation. In the present report, we describe two exceptional cases of HHV8-negative large B-cell effusion-based lymphoma (EBL) confined to the pleura, incidentally, diagnosed in patients presenting with dasatinib-related pleural effusion. One patient (case 1) is alive and is in remission at 17 months from large B-cell EBL diagnosis while unfortunately the other patient (case 2) died of progressive disease and COVID-19 pneumonia 16 months from large B-cell EBL diagnosis. These cases raise concern about a possible association between large B-cell EBL and dasatinib, and the different clinical outcome of the two cases poses a challenge in treatment decision. For this reason, we strongly recommend cytological investigation in patients with persistent/relapsing pleural effusion under dasatinib, primarily to validate its possible association with lymphoma development and to improve the knowledge about this entity.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (21198)
This publication has 16 references indexed in Scilit:
- A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemiaOncoTargets and Therapy, 2019
- Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemiaHaematologica, 2019
- Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaHaematologica, 2018
- Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVLeukemia, 2016
- Dasatinib-related Follicular HyperplasiaThe American Journal of Surgical Pathology, 2015
- Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsBlood, 2014
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaHaematologica, 2009
- EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemiaLeukemia, 2007
- Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent mannerBlood, 2005
- EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylateBlood, 2003